Recce Pharmaceuticals Ltd announces positive data from phase I/II clinical trial

Recce Pharmaceuticals Ltd (ASX: $RCE) has reported positive data from a Phase I/II clinical trial for urinary tract infections (UTIs) and urosepsis, demonstrating the safety and efficacy of RECCE® 327 (R327) against Escherichia coli (E. coli). The trial included 25 participants who received R327 at doses up to 4,000mg as intravenous infusions over various infusion times, with the highest dose cohort showing significant R327 activity in urine samples, particularly in the first hour post-dose.

Executive Commentary on RECCE® 327 Phase I/II Trial

Dr. Alan Dunton, Chief Medical Advisor at Recce Pharmaceuticals, commented on the positive outcomes from the clinical trial, highlighting R327's potential as a transformative treatment for serious and/or resistant bacterial infections, including complicated UTIs/urosepsis. Dr. Marc Sharp, Chief Scientific Officer at Linnaeus Bioscience, also expressed encouragement regarding R327's ability to achieve biologically relevant concentrations and exhibit anti-bacterial activity in urine samples.

Summary of RECCE® 327 Phase I/II Trial Results

The Phase I/II trial of RECCE® 327 demonstrated its safety and efficacy against E. coli, with sustained impact on bacterial growth in the urinary tract. The study successfully determined an optimal dosing regimen for R327, paving the way for the initiation of a Phase II trial in patients with urinary tract infections in the second half of 2024. The Company plans to explore additional therapeutic indications for R327 and investigate its potential in treating a broader range of bacterial infections beyond UTIs and urosepsis, addressing the global health threat posed by antibiotic-resistant pathogens.